U.S., April 10 -- ClinicalTrials.gov registry received information related to the study (NCT06919926) titled 'Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults' on April 02.
Brief Summary: This randomized, crossover, placebo controlled clinical study will assess the efficacy and safety of a slow release form of levetiracetam (AGB101) in the treatment of cognitively normal adults by measuring change in several imaging measures over the course of a two week treatment period.
Study Start Date: May 01
Study Type: INTERVENTIONAL
Condition:
Hippocampal Overactivity
Dementia
Intervention:
DRUG: AGB101
low-dose levetiracetam, 220 mg, extended release tablet
Recruitment Status: RECRUITING...